Eli Lilly | Sustainability Performance

https://www.lilly.com

Eli Lilly and Company engages in the research and development of pharmaceuticals. The company focuses on treatments across multiple disease areas.

1876

United States

10,001+ employees

Pharmaceuticals

$10B+ in revenue

$10B+ in profitability

Submit or report inaccurate data Download Company Insights

Sustainability Ranking & Industry Benchmark

#10433

Overall

#2348

in United States

#253

in Pharmaceuticals

Sustainability Maturity

Sustainability Intent

Available in
Scale package

Access

Industry Rank

53 out of 312

Overview

Environmental

Carbon emissionsEnergy consumptionWaste ManagementWater ManagementNature and biodiversityClimate risk

Social

Diversity and InclusionPay GapsHealth and SafetyExternalities

Governance

TargetsSDG ImpactESG scores and Exclusions

Financial Data

Business performanceCapital & innovationAnalyst projections

View similiar companies

Merck & Co.

United States, Hospital & Health Care, Pharmaceuticals

MSD for Mothers

United States, Hospital & Health Care, Pharmaceuticals

Pfizer

United States, Hospital & Health Care, Pharmaceuticals

CO2 scope 1 + 2

583.8K CO2e tonnes, 2024

Aligned

Renewable energy

20% 2024

Laggard

Waste generated

125.0K tonnes, 2024

Aligned

Female employees

52% 2025

Aligned

Externalities

475.8M $, 2025

Leading

Market cap

1.0T $, 2026▲33.9% YoY

Revenue

65.2B $, 2025▲30.9% YoY

R&D intensity

20.46% 2025

Intensity

Greenhouse gas intensity Scope 1, 2 (tCO₂e /$M)

Greenhouse gas intensity (Scope 1, 2, 3)(tCO₂e /$M)

Energy consumption (direct) intensity (MWh /$M)

Waste generation intensity (tonnes /$M)

Industry Benchmark

9.0

B/M 13.9

103.7

B/M 114.3

30.1

B/M 35.5

1.9

B/M 0.3

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Eli Lilly and Company — US pharmaceutical major (GLP-1 Mounjaro/Zepbound tirzepatide, Trulicity dulaglutide, Verzenio abemaciclib, Taltz ixekizumab) — has faced multiple US class actions over alleged inadequate disclosure of US/global GLP-1 Mounjaro/Zepbound customer demand including the contested 2024 sustained scrutiny over US compounding pharmacy GLP-1 customer compliance and the historic 2020 USD 9.5 million US DOJ Lilly Federal Trade Commission Generic Pharma alleged kickback settlement affecting US institutional shareholders.

Carbon emissions breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	-	-	*******	*******	*******	*******
*******	*******	-	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Energy consumption breakdown

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******

Biodiversity impact

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	-	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Waste management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	*******	*******	*******

Water management

Reveal data for 2 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	-	-	-	-	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	-	-	-	*******	*******
*******	*******	-	-	-	*******	*******	*******

Land use

Reveal data for 2 credits

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Diversity & inclusion

Reveal data for 3 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Pay gap breakdown

Reveal data for 1 credit

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

KPI	Metric	Year
	2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******

Externalities

Reveal data for 1 credit

KPI	Metric	Year
		2021	2022	2023	2024	2025	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

SDG impact (historical)

Reveal data for 5 credits

KPI	Metric	Year
		2020	2021	2022	2023	2024	Benchmark
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******
*******	*******	*******	*******	*******	*******	*******	*******

Reporting

Sustainability Report

Available

Sustainability employees

Available in
Scale package

Access

Controversy level

Very Low

Low

Noticeable

High

Severe

Download Controversy Analysis

Eli Lilly and Company — US pharmaceutical major (GLP-1 Mounjaro/Zepbound tirzepatide, Trulicity dulaglutide, Verzenio abemaciclib, Taltz ixekizumab) — has faced multiple US class actions over alleged inadequate disclosure of US/global GLP-1 Mounjaro/Zepbound customer demand including the contested 2024 sustained scrutiny over US compounding pharmacy GLP-1 customer compliance and the historic 2020 USD 9.5 million US DOJ Lilly Federal Trade Commission Generic Pharma alleged kickback settlement affecting US institutional shareholders.

Eli Lilly | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female employees

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Revenue by region

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Sustainability targets and commitments

Progress against targets

Environmental policy coverage

Overall score

Environment

Social

Governance

Exclusion screening

SDG impact

SDG impact (historical)

Reporting

Sustainability employees

Available in Scale package

Eli Lilly | Sustainability Performance

Sustainability Ranking & Industry Benchmark

Sustainability Maturity

Sustainability Intent

Available in Scale package

View similiar companies

Carbon emissions

Renewable energy

Renewable electricity

Intensity

Female employees

Waste

Controversy level

Carbon emissions breakdown

Energy consumption breakdown

Climate risk

Biodiversity loss in km²

Biodiversity loss in CO2e

Potential species loss

Biodiversity impact

Waste management

Water management

Land use

Diversity & inclusion

Pay gap breakdown

Health & safety

Externalities

Revenue & EBITDA

Revenue by region

Margin trends

R&D intensity

Return on invested capital

Analyst revenue estimates & actuals

Sustainability targets and commitments

Available in
Scale package

Available in
Scale package

Available in
Scale package

Available in
Scale package